BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 09-Nov-2020

The Board of Directors has recommended 10% cash dividend for the year ended on June 30, 2020. Date of AGM: 23.12.2020, Time: 4.00 PM, Venue: Digital Platform. Record Date: 29.11.2020. (Cont.)

ORIONPHARM 01-Nov-2020

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 08, 2020 at 5:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.

ORIONPHARM 31-May-2020

(Continuation news of ORIONPHARM): Consolidated NAV per share (excluding Revaluation Surplus) was Tk. 68.57 as on March 31, 2020 and Tk. 66.98 as on March 31, 2019. NAV per share (including Revaluation Surplus) was Tk. 76.68 as on March 31, 2020 and Tk. 74.29 as on March 31, 2019. (end)

ORIONPHARM 31-May-2020

(Q3 Un-audited): Consolidated EPS was Tk. 0.61 for January-March 2020 as against Tk. 0.95 for January-March 2019; Consolidated EPS was Tk. 2.75 for July'19-March'20 as against Tk. 3.01 for July'18-March'19. Consolidated NOCFPS was Tk. 2.73 for July'19-March'20 as against Tk. 7.15 for July'18-March'19. (cont.)

ORIONPHARM 18-Feb-2020

The Company has informed the following: "At this moment, there is no undisclosed material or price sensitive information of our Company which may cause current unusual upward trend in the price of our Company 's marketable securities. We want to request the investors to make their valuable investment decisions based on Company fundamentals, technical analysis, price level and disclosed information and most importantly, avoid rumor-based speculations."

ORIONPHARM 28-Jan-2020

(Continuation news of ORIONPHARM): Consolidated NAV per share including revaluation surplus was Tk. 75.73 as on December 31, 2019 and Tk. 75.19 as on June 30, 2019. Consolidated NAV per share excluding revaluation surplus was Tk. 67.58 as on December 31, 2019 and Tk. 66.98 as on June 30, 2019. (end)

ORIONPHARM 28-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 0.97 for October-December 2019 as against Tk. 1.08 for October-December 2018; Consolidated EPS was Tk. 2.14 for July-December 2019 as against Tk. 2.06 for July-December 2018. Consolidated NOCFPS was Tk. 3.11 for July-December 2019 as against Tk. 4.98 for July-December 2018. (cont.)

ORIONPHARM 23-Jan-2020

Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as "A1" along with a stable outlook based on audited financial statements as of June 30, 2019, bank liability position as of December 31, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

ORIONPHARM 22-Jan-2020

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2019 to the respective shareholders.

ORIONPHARM 22-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2020 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

Previous Next page